Abstract

The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (n = 9) and immunoglobulin-derived (n = 7). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.

Details

Title
Two types of amyloidosis presenting in a single patient: a case series
Author
Hasib, Sidiqi M 1 ; McPhail, Ellen D 2 ; Theis, Jason D 2 ; Dasari Surendra 3 ; Vrana, Julie A 2 ; Eleni, Drosou Maria 4 ; Leung, Nelson 5   VIAFID ORCID Logo  ; Hayman, Suzanne 1 ; Vincent, Rajkumar S 1   VIAFID ORCID Logo  ; Warsame Rahma 1 ; Ansell, Stephen M 1 ; Gertz, Morie A 1 ; Grogan, Martha 6 ; Dispenzieri, Angela 1 

 Mayo Clinic Rochester, Division of Hematology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Rochester, Department of Health Sciences Research, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Rochester, Division of Nephrology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Rochester, Division of Hematology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Rochester, Division of Nephrology, Department of Internal Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Department of Cardiovascular Diseases, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
Publication year
2019
Publication date
Mar 2019
Publisher
Springer Nature B.V.
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2188201306
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.